Needham & Company LLC reiterated their positive rating on shares of Dermira Inc. (NASDAQ:DERM) in a research report sent to investors on Monday morning. They currently have a $46.00 target price on the biopharmaceutical company’s stock.
Separately, Zacks Investment Research upgraded Dermira from a sell rating to a hold rating in a report on Wednesday, June 22nd. One analyst has rated the stock with a hold rating and four have assigned a buy rating to the stock. The stock presently has an average rating of Buy and a consensus target price of $41.00.
Dermira (NASDAQ:DERM) opened at 34.93 on Monday. The firm has a 50-day moving average price of $33.21 and a 200-day moving average price of $29.50. The stock’s market cap is $1.24 billion. Dermira has a 52 week low of $17.42 and a 52 week high of $36.16.
Dermira (NASDAQ:DERM) last issued its quarterly earnings data on Monday, August 8th. The biopharmaceutical company reported ($0.89) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.86) by $0.03. On average, equities research analysts predict that Dermira will post ($3.46) EPS for the current year.
In related news, VP Christopher M. Griffith sold 1,303 shares of the business’s stock in a transaction that occurred on Friday, July 15th. The stock was sold at an average price of $30.02, for a total value of $39,116.06. Following the completion of the sale, the vice president now directly owns 44,941 shares in the company, valued at $1,349,128.82. The sale was disclosed in a filing with the SEC, which is available at this link. Also, CFO Andrew Guggenhime sold 10,000 shares of the business’s stock in a transaction that occurred on Monday, July 11th. The shares were sold at an average price of $30.15, for a total value of $301,500.00. Following the completion of the sale, the chief financial officer now owns 14,375 shares of the company’s stock, valued at $433,406.25. The disclosure for this sale can be found here. 17.30% of the stock is owned by corporate insiders.
Several large investors have recently modified their holdings of the stock. JPMorgan Chase & Co. boosted its stake in shares of Dermira by 6,034.5% in the second quarter. JPMorgan Chase & Co. now owns 3,558 shares of the biopharmaceutical company’s stock valued at $104,000 after buying an additional 3,500 shares during the period. Glenmede Trust Co. NA bought a new stake in shares of Dermira during the second quarter valued at about $170,000. A.R.T. Advisors LLC bought a new stake in shares of Dermira during the second quarter valued at about $207,000. DIAM Co. Ltd. bought a new stake in shares of Dermira during the second quarter valued at about $231,000. Finally, Prudential Financial Inc. bought a new stake in shares of Dermira during the second quarter valued at about $253,000. Institutional investors and hedge funds own 82.46% of the company’s stock.
Dermira Company Profile
Dermira, Inc is a biopharmaceutical company. The Company is focused on identifying, developing and commercializing differentiated therapies for dermatologic diseases. The Company’s portfolio includes three late-stage product candidates that target unmet needs and market opportunities, such as Cimzia (certolizumab pegol), DRM04 and DRM01.
Receive News & Ratings for Dermira Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dermira Inc. and related companies with MarketBeat.com's FREE daily email newsletter.